Efficacy of PD-(L)1 inhibitors plus anlotinib in the second-line treatment of extensive-stage small cell lung cancer.

After Bonferroni correction, in patients who used immunotherapy in the first-line setting, second-line A nonsignificant trend toward better ORR and DCR was observed with I + A treatment versus chemotherapy alone (ORR: 24.3% vs. 10.0%, P = 0.128; DCR: 81.1% vs. 56.7%, P = 0.030) (Fig. 3 E and F).

also in 5,406 other papers

17.6%, P = 0.031), though the difference did not reach statistical significance(Fig. 2 A; Table 2 ).

also in 111,027 other papers